Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas

摘要: Purpose: Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) confer a strong sensitivity to gefitinib, selective inhibitor EGFR. Experimental Design: We examined EGFR at exons 18, 19, and 21 tumor tissue from 68 gefitinib-treated, chemorefractory, advanced non–small cell lung cancer patients United States, Europe, Asia highly gefitinib-sensitive line correlated their presence with response survival. In addition, subgroup 28 for whom remaining was available, we relationship among mutations, CA repeats intron 1 EGFR, caveolin-1 mRNA levels, increased gene copy numbers. Results: Seventeen had all which were adenocarcinomas. Radiographic observed 16 17 (94.1%) harboring contrast 6 51 (12.6%) wild-type ( P 9.9 months those = 0.001). tended be associated numbers but not overexpression significant). Conclusions: The is major determinant gefitinib response, targeting should considered preference chemotherapy as first-line treatment adenocarcinomas that have demonstrable mutations.